341 related articles for article (PubMed ID: 11575921)
21. Intrinsic U2AF binding is modulated by exon enhancer signals in parallel with changes in splicing activity.
Wang Z; Hoffmann HM; Grabowski PJ
RNA; 1995 Mar; 1(1):21-35. PubMed ID: 7489484
[TBL] [Abstract][Full Text] [Related]
22. Novel exploitation of a nuclear function by influenza virus: the cellular SF2/ASF splicing factor controls the amount of the essential viral M2 ion channel protein in infected cells.
Shih SR; Krug RM
EMBO J; 1996 Oct; 15(19):5415-27. PubMed ID: 8895585
[TBL] [Abstract][Full Text] [Related]
23. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
Dauksaite V; Akusjärvi G
Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
[TBL] [Abstract][Full Text] [Related]
24. Balanced splicing at the Tat-specific HIV-1 3'ss A3 is critical for HIV-1 replication.
Erkelenz S; Hillebrand F; Widera M; Theiss S; Fayyaz A; Degrandi D; Pfeffer K; Schaal H
Retrovirology; 2015 Mar; 12():29. PubMed ID: 25889056
[TBL] [Abstract][Full Text] [Related]
25. Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements.
Mayeda A; Screaton GR; Chandler SD; Fu XD; Krainer AR
Mol Cell Biol; 1999 Mar; 19(3):1853-63. PubMed ID: 10022872
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation-dephosphorylation differentially affects activities of splicing factor ASF/SF2.
Xiao SH; Manley JL
EMBO J; 1998 Nov; 17(21):6359-67. PubMed ID: 9799243
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA.
Ropers D; Ayadi L; Gattoni R; Jacquenet S; Damier L; Branlant C; Stévenin J
J Biol Chem; 2004 Jul; 279(29):29963-73. PubMed ID: 15123677
[TBL] [Abstract][Full Text] [Related]
28. The strength of the HIV-1 3' splice sites affects Rev function.
Kammler S; Otte M; Hauber I; Kjems J; Hauber J; Schaal H
Retrovirology; 2006 Dec; 3():89. PubMed ID: 17144911
[TBL] [Abstract][Full Text] [Related]
29. Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1.
Staffa A; Cochrane A
Mol Cell Biol; 1995 Aug; 15(8):4597-605. PubMed ID: 7623851
[TBL] [Abstract][Full Text] [Related]
30. An intron enhancer recognized by splicing factors activates polyadenylation.
Lou H; Gagel RF; Berget SM
Genes Dev; 1996 Jan; 10(2):208-19. PubMed ID: 8566754
[TBL] [Abstract][Full Text] [Related]
31. Human splicing factor ASF/SF2 encodes for a repressor domain required for its inhibitory activity on pre-mRNA splicing.
Dauksaite V; Akusjärvi G
J Biol Chem; 2002 Apr; 277(15):12579-86. PubMed ID: 11801589
[TBL] [Abstract][Full Text] [Related]
32. Exonic splicing enhancer motif recognized by human SC35 under splicing conditions.
Liu HX; Chew SL; Cartegni L; Zhang MQ; Krainer AR
Mol Cell Biol; 2000 Feb; 20(3):1063-71. PubMed ID: 10629063
[TBL] [Abstract][Full Text] [Related]
33. SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during differentiation of virus-infected epithelial cells.
McPhillips MG; Veerapraditsin T; Cumming SA; Karali D; Milligan SG; Boner W; Morgan IM; Graham SV
J Virol; 2004 Oct; 78(19):10598-605. PubMed ID: 15367627
[TBL] [Abstract][Full Text] [Related]
34. Binding sites for Rev and ASF/SF2 map to a 55-nucleotide purine-rich exonic element in equine infectious anemia virus RNA.
Chung H ; Derse D
J Biol Chem; 2001 Jun; 276(22):18960-7. PubMed ID: 11278454
[TBL] [Abstract][Full Text] [Related]
35. cis-Acting and trans-acting modulation of equine infectious anemia virus alternative RNA splicing.
Liao HJ; Baker CC; Princler GL; Derse D
Virology; 2004 May; 323(1):131-40. PubMed ID: 15165825
[TBL] [Abstract][Full Text] [Related]
36. Multiple ASF/SF2 sites in the human papillomavirus type 16 (HPV-16) E4-coding region promote splicing to the most commonly used 3'-splice site on the HPV-16 genome.
Somberg M; Schwartz S
J Virol; 2010 Aug; 84(16):8219-30. PubMed ID: 20519389
[TBL] [Abstract][Full Text] [Related]
37. A bidirectional SF2/ASF- and SRp40-dependent splicing enhancer regulates human immunodeficiency virus type 1 rev, env, vpu, and nef gene expression.
Caputi M; Freund M; Kammler S; Asang C; Schaal H
J Virol; 2004 Jun; 78(12):6517-26. PubMed ID: 15163745
[TBL] [Abstract][Full Text] [Related]
38. The SR splicing factors ASF/SF2 and SC35 have antagonistic effects on intronic enhancer-dependent splicing of the beta-tropomyosin alternative exon 6A.
Gallego ME; Gattoni R; Stévenin J; Marie J; Expert-Bezançon A
EMBO J; 1997 Apr; 16(7):1772-84. PubMed ID: 9130721
[TBL] [Abstract][Full Text] [Related]
39. The deep intronic c.903+469T>C mutation in the MTRR gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cblE type of homocystinuria.
Homolova K; Zavadakova P; Doktor TK; Schroeder LD; Kozich V; Andresen BS
Hum Mutat; 2010 Apr; 31(4):437-44. PubMed ID: 20120036
[TBL] [Abstract][Full Text] [Related]
40. Splicing inhibition of U2AF65 leads to alternative exon skipping.
Cho S; Moon H; Loh TJ; Jang HN; Liu Y; Zhou J; Ohn T; Zheng X; Shen H
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):9926-31. PubMed ID: 26216990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
